{"name":"Surface Oncology","slug":"surface","ticker":"SURF","exchange":"NASDAQ","domain":"surfaceoncology.com","description":"Surface Oncology is a clinical-stage immuno-oncology company focused on developing therapies that target the tumor microenvironment. The company's lead product candidate, monalizumab, is being investigated in multiple clinical trials for various types of cancer. Surface Oncology has a strong pipeline of innovative therapies, positioning it as a key player in the immuno-oncology market.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Rob Ross","sector":"Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$75M","metrics":{"revenue":30000000,"revenueGrowth":1016.5,"grossMargin":0,"rdSpend":67003000,"netIncome":-63586000,"cash":159910000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Monalizumab patent cliff ($0.0B at risk)","drug":"Monalizumab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Surface Oncology Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Surface Oncology reported its fourth quarter and full year 2023 financial results, highlighting progress in its clinical pipeline and strong cash position.","drugName":"","sentiment":"neutral"},{"date":"2023-12-05","type":"deal","headline":"Surface Oncology Announces Collaboration with Merck KGaA to Develop Novel Cancer Therapies","summary":"Surface Oncology entered into a collaboration with Merck KGaA to develop novel cancer therapies, expanding its pipeline and strengthening its position in the immuno-oncology market.","drugName":"","sentiment":"positive"},{"date":"2023-08-07","type":"trial","headline":"Surface Oncology Announces Positive Interim Results from Phase 1/2 Clinical Trial of Monalizumab in Combination with Nivolumab","summary":"Surface Oncology announced positive interim results from its Phase 1/2 clinical trial of monalizumab in combination with nivolumab, demonstrating promising efficacy and safety in patients with various types of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPLWkyeXU4YkdOUGpqR0VUQm0yRU4xZFZTMXFSMUJiVXpBMkNXM1pLd1piaW5tR0J3cEZBSE50WkdFYTlMX2Rra1hCRkVRcy02OXBqQW9YZy10MW5mMUJSdWlXMzV6eGhWY3RJWERjcFJKUGxSVWVuNFJOT3I0WHJ6clF2TlhEclNudEtZMkYyNUdZdGlUWlBZ?oc=5","date":"2023-09-08","type":"pipeline","source":"Yahoo Finance","summary":"Coherus Completes Surface Oncology Acquisition - Yahoo Finance","headline":"Coherus Completes Surface Oncology Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOVXlYamJBaEdZU0FlWjUzOU1xYm1wQlFPc0I1NXZVRm9vQU1OUlBBbnl3bS1uTFBvNGlzbkhjSmFucVo3b0h0VXVxLURsOVp6dDhvX1d6N2Qxb0JyUWJ4ekxmVkJSVnBoTzQwc2s3TjVjLUZfU1lCUGMwTGVmOXZ6ZzBYTVZ6aklPQklsaG1VOGIydm5ueE1iU3dxam50TDlSbGN3UlBlMA?oc=5","date":"2023-06-16","type":"deal","source":"Fierce Biotech","summary":"Coherus continues to scratch the Surface of life outside of biosimilars with $65M buy - Fierce Biotech","headline":"Coherus continues to scratch the Surface of life outside of biosimilars with $65M buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNUUxySFpKZlUyMGRIbTNXTGRVa2g2LUJ1OUE1Mi1pUEt0OVRmQXItQnR5STRZekFzY2Qza3lWSFc1aUJlWEI2MHZCWUlva09QdkFwN1hWNUZMUzJ5aWFGMVJqZ2tPblQ5bFFSNlNrQ1lBNF9iTkVNenI0MGpFTUZ3bW1nbEZzNzVJN1UtYVNELUh3UGVyV1lYa3NIRUlYb0Z2X0NxbVdEbElNMFBfOVFnUDVFQ29tdDZkcE9kYlBubEZPTU11Y0piTGdvdVJ4M184Um91T3RqR05ZNFBZV2RrYVlOeWVYbFlsbTl2ZFpFOUsxdWJEcTZIM2dnb2hsT2pjdVEtY1VUOUFXSi1kcmFPMmxSb2NWWGd4aXRFTGRLeXk4Szd4aHMzVzV3a0oyZw?oc=5","date":"2021-03-10","type":"trial","source":"GlobeNewswire","summary":"Surface Oncology to Present Preclinical Data for Lead - GlobeNewswire","headline":"Surface Oncology to Present Preclinical Data for Lead","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNbkxmdXNaaGExUHhJRzVGTHBTYUhwTW1OOFVMQ3poTjMwUUxIZ3dHQ1hEUUQwdl9SM3M4SUt6b1M1Tmp1dXRneE9oS2JGQW8xSEdwVXJjQlpmREd6VmtfRzlXUVcxd0dEdHVNRktBTkVoYTM0U1p3VlQ2eXlqT1RSQ3Zla3BkY3JHTmhHSnh0amNicmZPdlFUSzBXSFVITndmcWppZ09zQ1A3MURwVDFhUXpNT2pTdVBlZzdScTNzVEI1Q0IwLXF6ZDF3ZTBXdjlxeE9FcFphdGQxOTJLOVF1WGtmdVhqQmZtYjQ2cW10Z1QwY0s2VGg5bzJvQQ?oc=5","date":"2020-12-17","type":"deal","source":"GlobeNewswire","summary":"Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program - GlobeNewswire","headline":"Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNV3dnM04xXzVodU1GbG94Q2dRUl9OOGFvMG9RSkdqVUc3WGp1aHNMaDZBRG5qVFJVR1k3N2NoblUxVTI2bFlSX0JlNTRfRlNhT2RVUV85ZFBaMGNRZFQ5ZEtqdkpZV3NLS0h0RlktaThxV2NRaXlOX19qaFVoWC1ZRi1DMHQ0V0xFZXZDYnZKSTU2QTdLRkljaUxaQmtFb1VTQUprZ0k0OFM3RnNkajNhLXJPNUNYZDI1ZzFBVGZ4dmxBaldERjVJSEpDVU5XckxYRWhJWWUxUHo5UU5MakF3azRsVzRjeU9vYTFFRjVrZVVFdGJUWTg1X1RCUV8?oc=5","date":"2018-12-19","type":"pipeline","source":"proactiveinvestors.com","summary":"Surface Oncology pares lead program after tracking low-dose toxicity in drug targeting CD47 protein - proactiveinvestors.com","headline":"Surface Oncology pares lead program after tracking low-dose toxicity in drug targeting CD47 protein","sentiment":"neutral"}],"patents":[{"drugName":"Monalizumab","drugSlug":"monalizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Immuno-oncology","Tumor microenvironment"],"financials":{"source":"sec_edgar+yahoo","revenue":30000000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":30000000,"period":"2022-12-31"},{"value":2687000,"period":"2021-12-31"},{"value":2687000,"period":"2021-12-31"},{"value":126162000,"period":"2020-12-31"},{"value":126162000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":67003000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-63586000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":159910000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}